Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121828 | 0.83 | HTR4 (0.36) | MRGPRX4HTR4KAT8ALDH1A1CA14 | |
| SCHEMBL14969145 | 0.81 | HTR2C (0.43) | MRGPRX4HTR2CSLC6A4ALDH1A1TP53 | |
| SCHEMBL4134602 | 0.80 | L3MBTL1 (0.45) | MRGPRX4HTR2CSLC6A4METAP2ALDH1A1 | |
| SCHEMBL15808726 | 0.74 | MRGPRX4 (0.45) | MRGPRX4KAT8ALDH1A1TP53AKR1C2 | |
| SCHEMBL18147237 | 0.72 | ALDH1A1 (0.44) | KAT8ALDH1A1TP53LMNA | |
| SCHEMBL3084246 | 0.72 | CDK8 (0.42) | HTR2CSLC6A4ALDH1A1TP53CDK8 | |
| SCHEMBL30005928 | 0.72 | HDAC1 (0.35) | HTR2CSLC6A4METAP2ALDH1A1PDK2 | |
| SCHEMBL3087044 | 0.71 | CDK8 (0.41) | HTR2CSLC6A4ALDH1A1TP53CDK8 | |
| SCHEMBL28775341 | 0.71 | TACR1 (0.38) | HTR2CSLC6A4METAP2CA14PDK2 | |
| SCHEMBL14969499 | 0.70 | CYP4F2 (0.44) | HTR2CSLC6A4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
| EP-1862451-A1 | Adamantane derivatives for the treatment of inflammatory diseases | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| US-7297818-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2007-11-20 | — | — | US | disclosed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | disclosed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | MRGPRX4 2622/4885HTR4 1088/4885KAT8 3810/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | MRGPRX4 2407/4885HTR4 1652/4885KAT8 3972/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | MRGPRX4 2308/4885HTR4 621/4885KAT8 1431/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | MRGPRX4 2407/4885HTR4 1652/4885KAT8 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.